InnoCare Pharma reports strong revenue growth, significant loss reduction

For the first nine months of 2025, InnoCare Pharma Limited reported total operating revenue of RMB1.12 billion, a substantial 59.85% increase compared to the same period last year. This growth was largely driven by increased sales of its core product, orelabrutinib, and an upfront payment from an exclusive license agreement with Prolium Bioscience Inc. Net losses for the period were RMB72 million, a 74.78% reduction from the previous year, indicating improved financial performance.

Orelabrutinib sales revenue reached RMB1.01 billion, up 45.77% year-over-year, following its approval for a new indication in April 2025 for first-line treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. The company's gross profit margin also improved to 88.8%, an increase of 2.8 percentage points.

In a governance update, professor Kunliang Guan has been appointed to the nomination committee, while Ms. Lan Hu withdrew, effective November 13, 2025. This change aligns with amendments to the Corporate Governance Code, aiming to enhance committee diversity and overall corporate governance practices.